{"classes":[{"categories":[{"measurements":[{"comment":"Some participants were still alive without disease progression at the time of study completion.","groupId":"OG000","lowerLimit":"586","upperLimit":"NA","value":"661"},{"comment":"Some participants were still alive without disease progression at the time of study completion.","groupId":"OG001","lowerLimit":"821","upperLimit":"NA","value":"1694"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Calculate rate of progression-free survival for subjects following treatment BiRd regimen compared to Rd treatment regimen. Progression is determined by the International Myeloma Working Group Criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.\n\nClarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG000","title":"BiRD Treatment Regimen"},{"description":"Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG001","title":"Rd Treatment Regimen"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Until disease progression or death from any cause, for a maximum of approximately 5 years","title":"Survival Duration Without Disease Progression","type":"PRIMARY","unitOfMeasure":"days"}